作者:R. Villagomez、M. Quiroz、A. Tito、O. Sterner、G. R. Almanza
DOI:10.1007/s10600-015-1382-9
日期:2015.7
Damsin (1) is a pseudoguaianolide sesquiterpene possessing potent biological activities, reported as a metabolite of several medicinal plants belonging to the genus Ambrosia together with related compounds. Starting from 1, which can be isolated in good amounts from Ambrosia arborescens, the five natural pseudoguaianolides ambrosin (2), isodamsin (3), 3α-hydroxydamsin (4), 3α-acetoxydamsin (5), and 11β,13-dihydrodamsin (8) were prepared by regio- and stereo-selective synthetic modifications.
[EN] SYNTHESIS OF COMBRETASTATIN A-4 PRODRUGS AND TRANS-ISOMERS THEREO F<br/>[FR] SYNTHESE DE PROMEDICAMENTS A BASE DE COMBRESTATINE A-4 ET DE LEURS TRANS-ISOMERES
申请人:ARIZONA BOARD OF REGENTS, a body corporate, acting on behalf of ARIZONA STATE UNIVERSITY
公开号:WO1999035150A1
公开(公告)日:1999-07-15
(EN) Combretastatin A-4 has been previously selected for pre-clinical development as antineoplastic agents. However, it is essentially insoluble in water. New water soluble derivatives of combretastatin A-4 and its qualified analogs have been discovered and synthesized through a multistage process using other derivatives of combretastatin A-4 as intermediates. These water soluble derivatives are herein denominated as 'Combretastatin A-4 Prodrugs'.(FR) Selon cette invention, on a déjà utilisé la Combrestatine A-4 pour le développement préclinique, en tant qu'agent antinéoplasique; cependant, elle est généralement insoluble dans l'eau. On a découvert et synthétisé de nouveaux dérivés hydrosolubles de la Combrestatine A-4, ainsi que leurs analogues agréés, en passant par un procédé à plusieurs étapes et en utilisant comme intermédiaires d'autres dérivés de la Combrestatine A-4. Ces dérivés hydrosolubles sont désignés dans l'invention comme des 'promédicaments à base de Combrestatine A-4'.
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
申请人:CyDex, Inc.
公开号:EP1859790A2
公开(公告)日:2007-11-28
A multi-layered combined rapid and controlled release solid pharmaceutical formulation comprising:
at least one controlled release first layer comprising a physical mixture of a first therapeutic agent, a release rate modifier and a sulfoalkyl ether cyclodextrin for releasing said first therapeutic agent at a controlled rate into a first environment of use; and
at least one rapid release second layer comprising a physical mixture of a second therapeutic agent and a sulfoalkyl ether cyclodextrin for releasing said second therapeutic agent rapidly into a second environment of use;
wherein,
said first and second layers are juxtaposed; and
major portions of each of said first and second therapeutic agents are not complexed with said sulfoalkyl ether cyclodextrin.
The present invention provides an air scavenger composition comprising by weight at least: extracts of sanguisorba officinalis and melia azadarach 10-30 parts, extract of sophora flavescens 10-30 parts, extract of robinia pseudoacacia 5-10 parts, extract of eucalyptus leaves 1-5 parts, extract of chrysanthemum 10-15 parts, extract of aloe vera 10-15 parts, nanosilver 0.1-1 parts, and artemisinin 0.5-2 parts.
The present invention provides an air scavenger composition comprising by weight at least: extracts of sanguisorba officinalis and melia azadarach 10-30 parts, extract of sophora flavescens 10-30 parts, extract of robinia pseudoacacia 5-10 parts, extract of eucalyptus leaves 1-5 parts, extract of chrysanthemum 10-15 parts, extract of aloe vera 10-15 parts, nanosilver 0.1-1 parts, and artemisinin 0.5-2 parts.